Drug development in the ocular space has specific challenges. In this audiobook, we explore how an end-to-end solution can facilitate a path to Phase 2, and we do this by breaking down the entire pathway by solution.

Click here to read a PDF version of Issue 27: https://www.altasciences.com/sites/default/files/2022-09/The-Altascientist_issue-27_Ophthalmic_1.pdf

CHAPTERS:

- 0:54 — Section 1: Introduction

- 3:01 — Section 2: Prototype Development, Formulation, and Manufacturing

- 8:10 — Section 3: CDMO Case Study

- 10:40 — Section 4: Preclinical Research

- 17:38 — Section 5: Preclinical Case Study

- 23:30 — Section 6: Bioanalysis

- 32:32 — Section 7: Phase I Clinical Research

- 37:02 — Section 8: Clinical Case Study

- 40:42 — Section 9: Phase II to Commercialization

About Altasciences:

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.